A second cytoreductive surgery followed by platinum-based chemotherapy extended progression-free survival (PFS) compared with platinum-based chemotherapy alone in patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score.
David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
A single course of radiation treatment could relieve the symptoms of a spinal cord compression and maintain mobility as effectively as a multifractional course of radiotherapy (RT) in patients with advanced cancer, according to the results of a large phase III trial.
Updated results from the phase III MONALEESA-2 trial presented during the 2017 ASCO Annual Meeting confirmed the benefit of frontline ribociclib (Kisqali) in combination with letrozole in patients with postmenopausal hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The combination showed a progression-free survival (PFS) benefit of 9.3 months compared with letrozole plus placebo.
Chronic health issues, including high blood pressure, diabetes, erectile dysfunction, anxiety, or depression were noted in nearly 40% of testicular cancer survivors with low testosterone levels compared with survivors who had normal levels of testosterone, according to findings from a study that were released at the 2017 ASCO Annual Meeting.
Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.
Results from a recent study showed patients with stage III colorectal cancer experienced a 42% lower chance of death and a trend toward reduced cancer recurrence if they maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors.
Efficacy results for the human papillomavirus (HPV) vaccine continue to be impressive, with newly reported findings showing it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine.
More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.
Eating tree nuts, like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer, findings of a new prospective study suggest.
Overall survival was improved by 15 months for patients with macroscopically resected biliary tract cancer who were treated with adjuvant capecitabine compared with observation alone.
Christian G. Downs, JD, MHA, discusses his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission’s Part B cost control proposals, and the potential for progress in tackling rising drug costs.
Keeping patients on their oral oncology medications involves a combination of active management, record keeping, and coordination among healthcare workers, pharmacy professionals explained during a panel discussion.
Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Speakers at the 2017 Community Oncology Alliance (COA) annual meeting in National Harbor, Maryland, reflect on challenges in the first year of the OCM.
The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. “Skip” Burris III, MD.
Leah Ralph discusses the ACCC’s position on the ACA repeal bill, the Medicare Payment Advisory Commission’s (MedPAC) Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.
An April report from COA stated that PBMs have been calling patients and urging them to get their drugs from PBM-owned pharmacy networks, rather than through physician dispensaries. At this year’s Community Oncology Conference, presentations and discussions focused on this report.
Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.
Adding an immunotherapeutic agent to chemotherapy had no impact on survival in patients with recurrent, platinum-resistant ovarian cancer, according to a late-breaking trial reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
An immunotherapy targeting human papillomavirus-infected cells led to an unprecedented 1-year survival in patients with recurrent, metastatic cervical cancer, according to a phase II study reported at the 2017 Society of Gynecology Oncology Annual Meeting.
Maintenance chemotherapy failed to improve survival rates for women in complete remission from ovarian cancer after debulking surgery and adjuvant platinum-based chemotherapy, a large randomized trial showed.
Kathleen N. Moore, MD, discusses the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing, she says.
A 7-transcript classifiers effectively predicted metastatic disease for patients with endometrioid endometrial cancer, with added promise shown when the gene expression signature was combined with pathologic features.
Patients with relapsed, platinum-sensitive <em>BRCA</em>-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.
Patients with <em>BRCA</em>-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.
Mismatch repair–deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.
Ursula A. Matulonis, MD, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.